FDA Panel Backs Four Peptides; Scientists Still Question Their Identity

An FDA advisory committee has narrowly supported adding BPC-157, KPV, TB-500, and MOTS-c-related substances to the list of bulk ingredients that may be used by eligible 503A compounding pharmacies. The decision could reshape access to peptides already promoted across wellness